Related coverage linked through entity extraction aliases.
Apr 29, 2026
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Mar 31, 2026
Multiple Indian pharmaceutical companies including Zydus, Glenmark, Dr. Reddy's, and Alkem have launched semaglutide versions following patent expiry, dramatically reducing prices and expanding access. Companies are competing on both price and innovative delivery systems, with monthly therapy costs now ranging from Rs 1,300 to Rs 4,200. This development could significantly impact diabetes and obesity treatment in India, where over 100 million people live with diabetes.
Mar 24, 2026
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Mar 13, 2026
China's NMPA approved Desidustat Tablets on March 13, 2026, for treating anemia in non-dialysis CKD patients. Clinical trials showed the oral HIF-PHI was non-inferior to erythropoietin in maintaining hemoglobin levels with improved quality of life.
Mar 13, 2026
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Feb 27, 2026
Zydus Lifesciences received USFDA final approval for 32 mg bosentan tablets for pediatric PAH and Ammonium Lactate Cream, 12%, while launching an affordable respiratory device in India.
Feb 27, 2026
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
Feb 26, 2026
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
Feb 25, 2026
The patent for semaglutide, the active ingredient in Ozempic, expires March 20, 2026. Indian pharmaceutical companies are preparing to launch generic versions, with prices expected to be 30-50% lower than branded products.
Feb 25, 2026
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
Feb 15, 2026
Zydus Lifesciences Limited received final FDA approval for Ammonium Lactate Cream, 12%, a generic of Lac-Hydrin Cream. The topical prescription medication treats xerosis and ichthyosis vulgaris, with annual U.S. sales of $15 million.
Feb 13, 2026
Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.
Feb 13, 2026
Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.
Oct 01, 2025
The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.
